{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:57:07Z","timestamp":1792270627208,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03006-5","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T03:25:53Z","timestamp":1731036353000},"page":"510-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7748-6887","authenticated-orcid":false,"given":"Joshua S.","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Laidlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2006-5130","authenticated-orcid":false,"given":"Scott","family":"Caveney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-7336","authenticated-orcid":false,"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-6362","authenticated-orcid":false,"given":"Flavia C. L.","family":"Hoyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"3006_CR1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9:1133\u201341.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3006_CR2","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/lary.21847","volume":"121","author":"ZM Soler","year":"2011","unstructured":"Soler ZM, Wittenberg E, Schlosser RJ, Mace JC, Smith TL. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope. 2011;121:2672\u20138.","journal-title":"Laryngoscope"},{"key":"3006_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105947","volume":"166","author":"GW Canonica","year":"2020","unstructured":"Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947.","journal-title":"Respir Med"},{"key":"3006_CR4","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","volume":"370","author":"GM Gauvreau","year":"2014","unstructured":"Gauvreau GM, O\u2019Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102\u201310.","journal-title":"N Engl J Med"},{"key":"3006_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ni805","volume":"3","author":"V Soumelis","year":"2002","unstructured":"Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673\u201380.","journal-title":"Nat Immunol"},{"key":"3006_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5414\/ALX02296E","volume":"6","author":"L Klimek","year":"2022","unstructured":"Klimek L, Hagemann J, Welkoborsky HJ, et al. Epithelial immune regulation of inflammatory airway diseases: chronic rhinosinusitis with nasal polyps (CRSwNP). Allergol Select. 2022;6:148\u201366.","journal-title":"Allergol Select"},{"key":"3006_CR7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800\u20139.","journal-title":"N Engl J Med"},{"key":"3006_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/JAA.S413064","volume":"16","author":"TM Laidlaw","year":"2023","unstructured":"Laidlaw TM, Menzies-Gow A, Caveney S, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915\u201332.","journal-title":"J Asthma Allergy"},{"key":"3006_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2021.103325","volume":"43","author":"G Riva","year":"2022","unstructured":"Riva G, Tavassoli M, Cravero E, et al. Long-term evaluation of nasal polyposis recurrence: a focus on multiple relapses and nasal cytology. Am J Otolaryngol. 2022;43:103325.","journal-title":"Am J Otolaryngol"},{"key":"3006_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/lary.26391","volume":"127","author":"AS DeConde","year":"2017","unstructured":"DeConde AS, Mace JC, Levy JM, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127:550\u20135.","journal-title":"Laryngoscope"},{"key":"3006_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/all.14902","volume":"77","author":"GW Canonica","year":"2022","unstructured":"Canonica GW, Harrison TW, Chanez P, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2022;77:150\u201361.","journal-title":"Allergy"},{"key":"3006_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","volume":"9","author":"TW Harrison","year":"2021","unstructured":"Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase\u00a03b trial. Lancet Respir Med. 2021;9:260\u201374.","journal-title":"Lancet Respir Med"},{"key":"3006_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","volume":"145","author":"P Howarth","year":"2020","unstructured":"Howarth P, Chupp G, Nelsen LM, et al. Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol. 2020;145:1713\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"3006_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.18176\/jiaci.0391","volume":"30","author":"A Tiotiu","year":"2020","unstructured":"Tiotiu A, Oster JP, Roux PR, et al. Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study. J Investig Allergol Clin Immunol. 2020;30:49\u201357.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"3006_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/JAA.S363527","volume":"15","author":"C Hopkins","year":"2022","unstructured":"Hopkins C, Buchheit KM, Heffler E, et al. Improvement in health-related quality of life with dupilumab in patients with moderate-to-severe asthma with comorbid chronic rhinosinusitis with\/without nasal polyps: an analysis of the QUEST study. J Asthma Allergy. 2022;15:767\u201373.","journal-title":"J Asthma Allergy"},{"key":"3006_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/lary.29766","volume":"132","author":"AH Khan","year":"2022","unstructured":"Khan AH, Reaney M, Guillemin I, et al. Development of sinonasal outcome test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2022;132:933\u201341.","journal-title":"Laryngoscope"},{"key":"3006_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","volume":"34","author":"C Hopkins","year":"2009","unstructured":"Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol. 2009;34:447\u201354.","journal-title":"Clin Otolaryngol"},{"key":"3006_CR18","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2011.12.986","volume":"129","author":"RS Tepper","year":"2012","unstructured":"Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129:S65-87.","journal-title":"J Allergy Clin Immunol"},{"key":"3006_CR19","unstructured":"American Thoracic Society. Asthma Control Questionnaire (ACQ), http:\/\/www.thoracic.org\/members\/assemblies\/assemblies\/srn\/questionaires\/acq.php. Accessed 23 Nov 2023."},{"key":"3006_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1378\/chest.115.5.1265","volume":"115","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115:1265\u201370.","journal-title":"Chest"},{"key":"3006_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41687-019-0109-2","volume":"3","author":"G Globe","year":"2019","unstructured":"Globe G, Wiklund I, Mattera M, Zhang H, Revicki DA. Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma. J Patient Rep Outcomes. 2019;3:22.","journal-title":"J Patient Rep Outcomes"},{"key":"3006_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.anai.2018.02.005","volume":"120","author":"HK Won","year":"2018","unstructured":"Won HK, Kim YC, Kang MG, et al. Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset. Ann Allergy Asthma Immunol. 2018;120:389\u201394.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03006-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03006-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03006-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:03:24Z","timestamp":1738217004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03006-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03006-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joshua S. Jacobs has received fees for sponsored research, consultancy and speaking from AstraZeneca, Genentech, GSK, Regeneron Pharmaceuticals, and Teva Pharmaceuticals; Joseph K. Han has received consultancy fees from AstraZeneca, Genentech, Gossamer Bio, Novartis, Regeneron Pharmaceuticals, and Sanofi; Jason K. Lee has received research support from AstraZeneca, Genentech, GSK, Medexus, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi, and Takeda; has received fees for speakers bureau from Aralez Bio, AstraZeneca, GSK, Medexus, Merck, Mylan, Novartis, and Sanofi; and receives consultancy fees from and is an advisory committee member of AstraZeneca, GSK, Medexus, Novartis, Regeneron Pharmaceuticals, and Sanofi; Tanya M. Laidlaw has served on scientific advisory boards for Eli Lilly, GSK, Regeneron\u00a0Pharmaceuticals, and Sanofi; Nicole L. Martin, Christopher S. Ambrose, Neil Martin, and Joseph D.\u00a0Spahn are employees of AstraZeneca and may own stock or stock options in AstraZeneca; Scott Caveney is an employee of Amgen and owns stock in Amgen; Flavia C. L. Hoyte has received honoraria from AstraZeneca, Genentech, Sanofi and Teva Pharmaceuticals; has participated in research with Genentech and Sanofi, for which her institution has been remunerated; and her family owns stock in Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines and applicable regulatory requirements. Approvals were obtained from the Copernicus Central Institutional Review Board (Cary, NC, USA), and local independent ethics committees. All patients or their guardians provided written informed consent in accordance with local requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}